Dr. Joseph Ragaz

Medical Oncologist & Clinical Professor
Faculty of Medicine
School of Population & Public Health
The University of British Columbia, Vancouver, BC, Canada



Dr. Joseph Ragaz - Clinical, Academic and Research Activities


Dr. Ragaz is a Medical Oncologist, Breast Cancer Specialist and Clinical Professor at the School of Population and Public Health (SPPH), University of British Columbia (UBC), Vancouver, B.C., Canada.

CLINICAL ACTIVITIES, 1977-2018

During his 1977-2003 tenure at the British Columbia Cancer Agency [BCCA], Vancouver, BC, Dr. Ragaz subspecialized in Breast Cancer, developing multiple Clinical Research Initiatives, some of those helping with changes of National and International Breast Cancer practice guidelines.

From 2003 to 2008, Dr. Ragaz was the Director of the Oncology Program, McGill University Health Centre [MUHC], McGill University, Montreal, Quebec, Canada, where he helped to expand and modernize the MUHC Oncology activities.

2009 – 2018 (present): In 2009, Dr. Ragaz opened the Vancouver-based Oncology Counselling, Research and Prevention Clinic, dedicated to in-depth counselling of patients with established Cancer and for Breast Cancer Prevention. Problematic issues are frequently discussed with current local, national and international opinion leaders. In addition to the counseling activities, and if required, an informed second opinion is provided.

In February, 2018, Dr. Ragaz joined Inspire Health (https://www.inspirehealth.ca/) a Provincial Cancer facility aimed at offering comprehensive cancer support care for recently diagnosed cancer patients. At Inspire Health, Dr. Ragaz will expand the Oncology counselling sessions to involve patient group counselling workshops and will coordinate the academic and physician educational activities.

ACADEMIC RESEARCH & UNIVERSITY TEACHING

Since 1977, Dr. Ragaz and his team have initiated and completed a number of national and international breast cancer studies, paving the way to concepts eventually accepted by the international community. These initiatives include projects such as:

After 2003, Dr. Ragaz started a chain of breast cancer epidemiology outcome projects, such as impact of optimum guidelines on long-term Breast Cancer incidence and mortality comparing Provinces of Canada; impact of HRT (hormone replacement therapy) on long-term multiple-cause outcomes; or an important still ongoing project, proposed to his Chinese collaborators, analyzing the impact of “Westernization” versus “Western therapies” on Breast Cancer Outcomes - comparing Rural versus Urban China, and Canada.

2009-2018: Dr. Ragaz is currently active at the School of Population and Public Health [SPPH], University of British Columbia, working with teams of local and international academic collaborators on a variety of Cancer Epidemiology and Outcome projects.

Some of them, such as the Public Health Impact of the modern generation HRT, or a proposal for Oncotype DX identifying in Breast Cancer Chemotherapy resistance, will likely impact the present management guidelines. Most of these projects were already presented between 2007 and 2016 at international forums such as ASCO & SABCS (see below "Ongoing Clinical Projects"), and are now reaching maturity and completion.

Between 2010 and 2015, Dr. Ragaz led, at UBC’s SPPH, a Postgraduate course (SPPH 524, Introduction to Medicine - the Public Health Perspective), for SPPH Masters and PhD students.

PATIENT ADVOCACY

2005-2017: Board Member, Director, Cancer Advocacy Coalition of Canada (http://www.canceradvocacy.ca). Dr. Ragaz has been an active champion of patient's rights to access the best cancer care, as seen from his many activities and publications with the Cancer Advocacy Coalition of Canada.

Ongoing Clinical Projects, 2016-2018

1. Ragaz J, Shakeraneh S, Wilson KS, Frohlich J, Qian H, Wong H, and Spinelli JJ : Emerging paradigms of Estrogen-based HRT: Review Analyses of Breast Cancer, Cardiac Events and all-cause Event & Mortality outcomes. A Critical Review with guideline implications. 2018, Manuscript in Preparation [MIP].

2. Ragaz J, Coldman A, Wilson KS, Fox J, Shakeraneh S, Wong H, and Spinelli JJ : Long-term breast cancer outcomes in Canada with special analyses of cancer care access and mortality reduction. 2018, MIP.

3. Ju-Yoon Y, Ragaz J, and Simpson J : Pathological basis of the DCIS: Impact of early diagnosis. 2018, MIP.

4. Ragaz J, Wong H, and Qian H : Comparative Analysis of Breast Cancer (BrCa) Incidence and Mortality Rates among Regions of Canada between 1950 and 2004: Impact of Systemic and Diagnostic Guidelines after 1977. 2018, MIP.

5. Ragaz J, Zheng Y, Chen JG, Bao PP, Shakeraneh S, Hu X, Fox J, Wong H, Qian H, Wilson KS, Simpson J, Spinelli JJ, and Coldman A : Breast Cancer Outcomes in Urban and Rural China: Adverse Effects of Western Lifestyle, versus Benefits of Western Interventions. A Comparative Analysis with Canada.. 2018, MIP.

6. Ragaz J, Qian H, Shakeraneh S, Fox J, Wilson KS, Simpson J, Yoon Y, and Wong H : Population rates of In-Situ breast cancer [DCIS] are associated with breast cancer (BrCa) Incidence and Mortality rates. A case for screening mammography. 2018, MIP.

7. Ragaz J, Coldman A, Fox J, Wilson KS, Shakeraneh S, Zheng Y, Spinelli JJ, Bao PP, Wong H, Simpson JS, Hu XC, and Chen JG : Breast cancer incidence among young women of urban China (Shanghai) and in Canada: Implications for prevention. 2018, MIP.

8. Ragaz J, Wilson KS, Wong H, et al. : Molecular Classification with 21 Gene Assay (Oncotype DX®) in 362,398 ER Positive Breast Cancer Patients: Definition of Chemoresistance with guideline implications.. 2018, MIP.

9. Ragaz J, Brodie A, Simpson J, Jelacic D, Shakeraneh S, Spinelli JJ, and Hayes M : Cox-2 expression and impact of Cox-2 on Breast Cancer survival according to Aromatase and ER status: Implications to or for Breast Cancer therapy with Aromatase and Cox2 Inhibitors. 2018, MIP.